肺腺癌驱动基因与静脉血栓栓塞症相关性研究

国际肿瘤学杂志››2021,Vol. 48››Issue (6): 370-373.doi:10.3760/cma.j.cn371439-20201119-00071

肺腺癌驱动基因与静脉血栓栓塞症相关性研究

李甜甜¹, 石莉程², 孔辉¹, 齐栩¹()

¹南京医科大学第一附属医院呼吸与危重症医学科 210029
²南京医科大学附属老年医院呼吸内科 210029

收稿日期:2020-11-19修回日期:2020-12-28出版日期:2021-06-08发布日期:2021-06-24
通讯作者:齐栩 E-mail:qixuly@163.com
基金资助:
江苏省卫生健康委科研项目(LGY2018054);江苏省卫生健康委科研项目(H2019029);北京医卫健康公益基金(F2135E)

Research on the correlation between driver genes of lung adenocarcinoma and venous thromboembolism

Li Tiantian¹, Shi Licheng², Kong Hui¹, Qi Xu¹()

¹Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
²Department of Respiratory Medicine, Geriatric Hospital of Nanjing Medical University, Nanjing 210029, China

Received:2020-11-19Revised:2020-12-28Online:2021-06-08Published:2021-06-24
Contact:Qi Xu E-mail:qixuly@163.com
Supported by:
Scientific Research Project of Health Commission of Jiangsu Province of China(LGY2018054);Scientific Research Project of Health Commission of Jiangsu Province of China(H2019029);Beijing Medical and Health Foundation(F2135E)

摘要/Abstract

摘要：

静脉血栓栓塞症(VTE)是肺腺癌的常见并发症。肺腺癌的驱动基因状态与VTE发生风险有关,常见的驱动基因包括表皮生长因子受体、间变性淋巴瘤激酶、c-ros原癌基因1酪氨酸激酶和Kirsten大鼠肉瘤病毒癌基因等。基于肺腺癌驱动基因与VTE之间的相关性研究,根据驱动基因状态筛选出发生VTE风险高的患者,最终将常规危险因素与驱动基因联合应用评估肺腺癌并发VTE的风险,对于临床早期预防肺腺癌患者发生VTE意义重大。

关键词:肺肿瘤,腺癌,静脉血栓栓塞,驱动基因

Abstract:

Venous thromboembolism (VTE) is one of the common complications of lung adenocarci-noma. The state of the driver genes of lung adenocarcinoma is related to the risk of VTE. The common driver genes include epidermal growth factor receptor, anaplastic lymphoma kinase, c-ros oncogene 1 receptor kinase and Kirsten rat sarcoma viral oncogene,etc.. Based on the study of the correlation between lung adenocarci-noma driver genes and VTE, it is of great significance for the early clinical prevention of VTE in patients with lung adenocarcinoma to screen out patients with high risk of VTE according to the state of the driver genes and finally evaluate the risk of VTE in patients with lung adenocarcinoma by combining conventional risk factors with the driver genes.

Key words:Lung neoplasms,Adenocarcinoma,Venous thromboembolism,Driver gene

李甜甜, 石莉程, 孔辉, 齐栩. 肺腺癌驱动基因与静脉血栓栓塞症相关性研究[J]. 国际肿瘤学杂志, 2021, 48(6): 370-373.

Li Tiantian, Shi Licheng, Kong Hui, Qi Xu. Research on the correlation between driver genes of lung adenocarcinoma and venous thromboembolism[J]. Journal of International Oncology, 2021, 48(6): 370-373.

参考文献32

[1]	Sheth RA, Niekamp A, Quencer KB, et al. Thrombosis in cancer patients: etiology, incidence, and management[J]. Cardiovasc Diagn Ther, 2017,7(Suppl 3):S178-S185. DOI: 10.21037/cdt.2017.11.02. doi:10.21037/cdt
[2]	Zer A, Moskovitz M, Hwang DM, et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism[J]. Clin Lung Cancer, 2017,18(2):156-161. DOI: 10.1016/j.cllc.2016.10.007. doi:10.1016/j.cllc.2016.10.007
[3]	Ades S, Kumar S, Alam M, et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer[J]. J Thromb Haemost, 2015,13(6):998-1003. DOI: 10.1111/jth.12910. doi:10.1111/jth.12910pmid:25809746
[4]	Mir Seyed Nazari P, Riedl J, Preusser M, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous throm-boembolism[J]. J Thromb Haemost, 2018,16(6):1121-1127. DOI: 10.1111/jth.14129. doi:10.1111/jth.14129pmid:29676036
[5]	Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis[J]. Blood, 2014,124(7):1062-1069. DOI: 10.1182/blood-2014-05-578435.
[6]	Guo J, Deng QF, Xiong W, et al. Comparison among different pre-sentations of venous thromboembolism because of lung cancer[J]. Clin Respir J, 2019,13(9):574-582. DOI: 10.1111/crj.13060. doi:10.1111/crj.v13.9
[7]	Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA, 2014,311(19):1998-2006. DOI: 10.1001/jama.2014.3741. doi:10.1001/jama.2014.3741
[8]	Zhang M, Wu S, Hu C. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis[J]. J Int Med Res, 2020,48(1):300060519896919. DOI: 10.1177/0300060519896919.
[9]	Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways[J]. Cancers (Basel), 2017,9(5):52. DOI: 10.3390/cancers9050052. doi:10.3390/cancers9050052
[10]	Evans M, O'Sullivan B, Smith M, et al. Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18 920 non-small cell lung cancer cases[J]. Pathol Oncol Res, 2019,25(4):1401-1409. DOI: 10.1007/s12253-018-0460-2. doi:10.1007/s12253-018-0460-2
[11]	Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells[J]. Blood, 2010,116(5):815-818. DOI: 10.1182/blood-2009-10-250639.
[12]	Noël-Savina E, Paleiron N, Le Gal G, et al. Mutation EGFR dans les adénocarcinomes broncho-pulmonaires: facteur de risque de MVTE?[J]. Rev Mal Respir, 2012,29(9):1137-1140. DOI: 10.1016/j.rmr.2012.09.012. doi:10.1016/j.rmr.2012.09.012pmid:23200589
[13]	Wang J, Hu B, Li T, et al. The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism[J]. Ann Transl Med, 2019,7(23):724. DOI: 10.21037/atm.2019.12.24. doi:10.21037/atm
[14]	Corrales-Rodriguez L, Soulières D, Weng X, et al. Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study[J]. Thromb Res, 2014,133(1):48-51. DOI: 10.1016/j.thromres.2013.10.042. doi:10.1016/j.thromres.2013.10.042
[15]	Verso M, Chiari R, Mosca S, et al. Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma[J]. Thromb Res, 2015,136(5):924-927. DOI: 10.1016/j.thromres.2015.09.006. doi:10.1016/j.thromres.2015.09.006
[16]	Davidsson E, Murgia N, Ortiz-Villalón C, et al. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma[J]. Multidiscip Respir Med, 2017,12:16. DOI: 10.1186/s40248-017-0097-0. doi:10.1186/s40248-017-0097-0
[17]	Dou F, Li H, Zhu M, et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer[J]. Respir Res, 2018,19(1):88. DOI: 10.1186/s12931-018-0791-2. doi:10.1186/s12931-018-0791-2
[18]	Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007,448(7153):561-566. DOI: 10.1038/nature05945. doi:10.1038/nature05945
[19]	Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007,131(6):1190-1203. DOI: 10.1016/j.cell.2007.11.025. doi:10.1016/j.cell.2007.11.025
[20]	Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers[J]. J Clin Oncol, 2012,30(8):863-870. DOI: 10.1200/jco.2011.35.6345. doi:10.1200/JCO.2011.35.6345
[21]	Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer[J]. Clin Cancer Res, 2012,18(17):4570-4579. DOI: 10.1158/1078-0432.Ccr-12-0550. doi:10.1158/1078-0432.CCR-12-0550
[22]	Neel DS, Allegakoen DV, Olivas V, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins[J]. Cancer Res, 2019,79(3):546-556. DOI: 10.1158/0008-5472.Can-18-1492. doi:10.1158/0008-5472.CAN-18-1492
[23]	Ng TL, Smith DE, Mushtaq R, et al. ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events[J]. J Thorac Oncol, 2019,14(4):596-605. DOI: 10.1016/j.jtho.2018.12.001. doi:10.1016/j.jtho.2018.12.001
[24]	Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phaseⅡ, prospective, multicenter, two-arms trial (METROS)[J]. Clin Lung Cancer, 2020,21(1):15-20. DOI: 10.1016/j.cllc.2019.06.012. doi:S1525-7304(19)30154-8pmid:31607443
[25]	Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020,19(3):1997-2007. DOI: 10.3892/etm.2020.8454.
[26]	Roskoski R Jr. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers[J]. Pharmacol Res, 2018,135:239-258. DOI: 10.1016/j.phrs.2018.08.013. doi:10.1016/j.phrs.2018.08.013
[27]	El Osta B, Behera M, Kim S, et al. Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience[J]. J Thorac Oncol, 2019,14(5):876-889. DOI: 10.1016/j.jtho.2019.01.020. doi:10.1016/j.jtho.2019.01.020
[28]	Linardou H, Kotoula V, Kouvatseas G, et al. Genotyping KRAS and EGFR mutations in Greek patients with mon-small-cell lung cancer: incidence, significance and implications for treatment[J]. Cancer Genomics Proteomics, 2019,16(6):531-541. DOI: 10.21873/cgp.20155. doi:10.21873/cgp.20155pmid:31659106
[29]	Graf C, Ruf W. Tissue factor as a mediator of coagulation and signaling in cancer and chronic inflammation[J]. Thromb Res, 2018,164(Suppl 1):S143-S147. DOI: 10.1016/j.thromres.2018.01.023. doi:10.1016/j.thromres.2018.01.023
[30]	Unruh D, Horbinski C. Beyond thrombosis: the impact of tissue factor signaling in cancer[J]. J Hematol Oncol, 2020,13(1):93. DOI: 10.1186/s13045-020-00932-z. doi:10.1186/s13045-020-00932-z
[31]	Yang S, Yang L, Wu Y, et al. Anaplastic lymphoma kinase rea-rrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma[J]. Ann Transl Med, 2020,8(20):1307. DOI: 10.21037/atm-20-6619. doi:10.21037/atm
[32]	Regina S, Rollin J, Bléchet C, et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation[J]. J Thorac Oncol, 2008,3(7):689-697. DOI: 10.1097/JTO.0b013e31817c1b21. doi:10.1097/JTO.0b013e31817c1b21